Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 6NIH 2NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 48Myeloid 25Lymphoid 7Breast 6Tumor-Agnostic 3Genitourinary 3Plasma cell 2Thoracic 1Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Dasatinib × Plasma cell × Clear all
NCT00560352 2017-03-13

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Bristol-Myers Squibb

Phase 1 Terminated
16 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT00560391 2016-08-04

Dasatinib in Combination With Revlimid (and Dexamethasone)

Bristol-Myers Squibb

Phase 1 Completed
35 enrolled 18 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡